title: Predictors of recurrence in surgical stage II endometrial adenocarcinoma.
abstract: OBJECTIVE
  A retrospective review of surgical stage II endometrial carcinoma was performed to evaluate clinical course, treatment, recurrence rate, and survival.
  
  
  METHODS
  A list of patients with clinical and surgical stage II endometrial carcinoma was obtained through the tumor registry and from the pathology department from 1988 to 1996. Data were collected on all cases of patients with endometrial carcinoma meeting stage II criteria by FIGO surgical staging. Variables including stage, histology, grade, lymph vascular space invasion (LVI), type and extent of surgery, radiation type and amount, smoking, menstrual status, parity, and age were evaluated for their predictive ability of disease recurrence. Cox proportional hazard regression models were used to examine the potential predictors of time to relapse univariately and multivariately.
  
  
  RESULTS
  Of patients identified, 65 underwent primary surgical staging. Only adenocarcinomas were included. Mean follow-up time was 4.7 years (range 0.2-9.6 years). Postoperative radiation was given to 85.7% of patients. There were 10 patients (15.4%) with recurrence of disease with a mean time to recurrence of 25 months. Five-year disease-specific survival was 93%. The only significant predictor of time to relapse was LVI (P = 0.002) in the multivariate analysis.
  
  
  CONCLUSIONS
  This retrospective review suggests that primary surgery followed by postoperative radiation therapy gives excellent results in surgical stage II disease. LVI appears to be a strong predictor of disease recurrence regardless of postoperative radiation therapy. It is difficult to draw conclusions about the type and amount of radiation given because recurrence rate is so low; however, it is reasonable to continue adjuvant radiation especially in cases where LVI is identified.
authors.affiliation: Vincent Gynecology, Division of Gynecologic Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.
authors.forename: C M
authors.initials: CM
authors.lastname: Feltmate
authors.forename: L R
authors.initials: LR
authors.lastname: Duska
authors.forename: Y
authors.initials: Y
authors.lastname: Chang
authors.forename: C E
authors.initials: CE
authors.lastname: Flynn
authors.forename: N
authors.initials: N
authors.lastname: Nikrui
authors.forename: E
authors.initials: E
authors.lastname: Kiggundu
authors.forename: A
authors.initials: A
authors.lastname: Goodman
authors.forename: A F
authors.initials: AF
authors.lastname: Fuller
authors.forename: J F
authors.initials: JF
authors.lastname: McIntyre
mesh_terms: D000230:Adenocarcinoma / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016889:Endometrial Neoplasms / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology*; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D012189:Retrospective Studies; D015996:Survival Rate